welcome
Reuters

Reuters

Health

Health

Novartis agrees to acquire Anthos for up to $3.1 billion

Reuters
Summary
Nutrition label

79% Informative

Anthos Therapeutics was founded by Blackstone Life Sciences and Novartis in 2019 to develop, manufacture, and commercialize abelacimab, a treatment to prevent stroke and the recurrence of blood clots.

The transaction is expected to close in the first half of this year .

VR Score

88

Informative language

95

Neutral language

46

Article tone

formal

Language

English

Language complexity

62

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links